Ste7 Inhibitors, as a chemical class, primarily consist of compounds that target the MAPK/ERK pathway, with a specific focus on inhibiting MEK1 and MEK2, the direct upstream activators of Ste7. These inhibitors are vital in the study of the MAPK pathway's regulation, offering insights into the complex network of kinases and their interactions. The inhibition of MEK1/2, and thus indirectly Ste7, provides a means to dissect the role of these kinases in various cellular processes. MEK inhibitors, which form the core of Ste7 inhibitors, operate by binding to the ATP-binding sites or the allosteric sites of MEK1/2. This binding action impedes the kinase activity of MEK1/2, preventing the phosphorylation and subsequent activation of downstream kinases, including Ste7. The efficacy of these inhibitors is closely linked to their selectivity and cellular permeability, crucial factors for their effective use in research studies. The chemical structures of these inhibitors are designed to achieve high affinity and specificity towards MEK1/2, making them effective tools in studies requiring precise modulation of the MAPK pathway.
Ste7 inhibitors serve as important agents in understanding signal transduction mechanisms. They are particularly significant in studying the cellular responses to various external stimuli, such as growth factors and stress. The inhibition of MEK and the consequent impact on Ste7 activity are of interest in research focused on the dynamics of cell signaling pathways. The development of these inhibitors has evolved to prioritize specificity and minimal off-target effects. Advanced compounds in this category, like Trametinib and Cobimetinib, are characterized by their selective inhibition of MEK1/2, offering targeted intervention in the MAPK pathway. Research in this field continuously seeks to enhance the pharmacokinetic and pharmacodynamic properties of these inhibitors, aiming for improved efficacy and specificity. Ste7 inhibitors, therefore, represent a key class of compounds in the study of kinase regulation and signal transduction, providing essential tools for unraveling the complexities of cellular signaling networks.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is upstream of Ste7, thereby reducing Ste7 activation. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is known to inhibit MEK1/2, thus indirectly affecting Ste7 function in the MAPK pathway. | ||||||
PD 184,352 | 212631-79-3 | sc-202759 sc-202759A | 1 mg 5 mg | $40.00 $260.00 | 34 | |
CI-1040 (PD 184,352) specifically targets MEK1/2, upstream regulators of Ste7, and impedes their activity. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib (AZD6244) is a potent MEK1/2 inhibitor, thereby indirectly influencing Ste7 activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that indirectly affects Ste7 by inhibiting its upstream activators. | ||||||
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $245.00 $428.00 | 1 | |
Binimetinib (BAY 869766) targets MEK1/2, which are upstream of Ste7, and can indirectly inhibit Ste7. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib inhibits MEK, thus indirectly affecting the activation state of Ste7. | ||||||
TAK-733 | 1035555-63-5 | sc-364630 sc-364630A | 5 mg 10 mg | $340.00 $640.00 | 1 | |
TAK-733, a MEK inhibitor, indirectly impedes Ste7 by targeting upstream kinases. | ||||||